Share:
98% compliance observed with Trogarzo
®
MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) Theratechnologies Inc. (Theratechnologies, or Company) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported on positive results presented in two separate posters in conjunction with ACTHIV 2021 virtual conference being held May 20-22, 2021.
The first poster
1 included findings from a survey conducted among 30 Trogarzo
® (ibalizumab-uiyk) patients to assess real-world patient experience and acceptance of IV administration. The survey found that 100 percent of patients were either very satisfied or moderately satisfied with their experience with Trogarzo
® (87 and 13 percent respectively). Other highlights included:
60 percent said that their experience with Trogarzo